Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells

Oncology Reports

Volumn 33, Issue 3, 2015, Pages 1395-1401

  Choi, Jung Eun ^a,b   Woo, Seon Min ^a   Min, Kyoung Jin ^a   Kang, Su Hwan ^b   Lee, Soo Jung ^b   Kwon, Taeg Kyu ^a  

^a Keimyung University School of Medicine   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

Author keywords

ABT 737; Bcl 2; C FLIP; Mcl 1; VX 680

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALISERTIB; BARASERTIB; FLICE INHIBITORY PROTEIN; PROTEIN BCL 2; TOZASERTIB; ABT-737; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AURORA A KINASE; BIPHENYL DERIVATIVE; CFLAR PROTEIN, HUMAN; DRUG COMBINATION; MCL1 PROTEIN, HUMAN; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN MCL 1; SULFONAMIDE;

APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; DOWN REGULATION; DRUG COMBINATION; DRUG EFFECTS; FEMALE; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASE A; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; DRUG COMBINATIONS; FEMALE; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84921646738     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3728     Document Type: Article

References (25)

1. Yip KW and Reed JC: Bcl-2 family proteins and cancer. Oncogene 27:6398-6406, 2008.
2. Certo M, Del Gaizo Moore V, Nishino M, et al: Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365, 2006.
3. Kim H, Rafiuddin-Shah M, Tu HC, et al: Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 8:1348-1358, 2006.
4. Oltersdorf T, Elmore SW, Shoemaker AR, et al: An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681, 2005.
5. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD and Letai A: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112-121, 2007.
6. Chauhan D, Velankar M, Brahmandam M, et al: A novel Bcl-2/Bcl-X (L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 26:2374-2380, 2007.
7. Konopleva M, Contractor R, Tsao T, et al: Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388, 2006.
8. van Delft MF, Wei AH, Mason KD, et al: The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399, 2006.
9. Andrews PD, Knatko E, Moore WJ and Swedlow JR: Mitotic mechanics: the auroras come into view. Curr Opin Cell Biol 15:672-683, 2003.
10. Hirota T, Kunitoku N, Sasayama T, et al: Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 114:585-598, 2003.
11. Farag SS: The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol 155:561-579, 2011.
12. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr and Gandara DR: Aurora kinases as anticancer drug targets. Clin Cancer Res 14:1639-1648, 2008.
13. Gritsko TM, Coppola D, Paciga JE, et al: Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9:1420-1426, 2003.
14. Katayama H, Brinkley WR and Sen S: The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451-464, 2003.
15. Tallarida RJ: Drug synergism: its detection and applications. J Pharmacol Exp Ther 298:865-872, 2001.
16. Mitchell T and Sugden B: Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69:2968-2976, 1995.
17. Harrington EA, Bebbington D, Moore J, et al: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10:262-267, 2004.
18. Pugazhenthi S, Miller E, Sable C, et al: Insulin-like growth factor-I induces bcl-2 promoter through the transcription factor cAMP-response element-binding protein. J Biol Chem 274:27529-27535, 1999.
19. Tamatani M, Che YH, Matsuzaki H, et al: Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem 274:8531-8538, 1999.
20. Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene 20:7342-7351, 2001.
21. Bourgarel-Rey V, Savry A, Hua G, et al: Transcriptional downregulation of Bcl-2 by vinorelbine: identification of a novel binding site of p53 on Bcl-2 promoter. Biochem Pharmacol 78:1148-1156, 2009.
22. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095-2097, 1994.
23. Wu Y, Mehew JW, Heckman CA, Arcinas M and Boxer LM: Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 20:240-251, 2001.
24. Ciechanover A and Schwartz AL: The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim Biophys Acta 1695:3-17, 2004.
25. Song JH, Kandasamy K and Kraft AS: ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 283:25003-25013, 2008.